At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 129 enrolled
Drug / intervention
Placebo +4 moredrug
Likely dose
MSDC-0602 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
In Brief
A Phase 2 clinical trial evaluating Placebo, MSDC-0602 100 mg, and 2 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 129 participants across 14 sites.
Detailed Summary
The purpose of this study is to assess the safety and tolerability of MSDC-0602 and to evaluate the reduction in fasting plasma glucose in patients with Type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2011
Enrollment StartFeb 2011
Primary CompletionJun 2011
TodayJul 2026
First PostedJan 21, 2011
Enrollment StartFeb 1, 2011
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 15.4 years ago
Interventions
Placebodrug
Placebo Capsules
MSDC-0602 100 mgdrug
MSDC-0602 100 mg Capsules
MSDC-0602 250 mgdrug
MSDC-0602 250 mg Capsules
MSDC-0602 250 mgdrug
MSDC-0602 500 mg Capsules
Pioglitazonedrug
Pioglitazone 45 mg Capsules